Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Retrovirus Free Cell Line for Vaccine Development

Technology #95149

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
Retrovirus Free Cell LineRetrovirusVaccineVirus
Categories
Researchers
Douglas Foster, PhD
Professor Emeritus, School of Veterinary Medicine
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

Immortalized cell lines for virus growth

US Patent Pending 5879924

Retrovirus Contamination Causes Side Effects and Recall of Vaccines

Advances in vaccine development have led to a renewed interest in their use for prevention and treatment of diseases such as HPV, cancer, and communicable disease. Ensuring that new vaccines are not only effective, but also safe and free of contaminants including retroviruses is one of the major challenges facing vaccine makers. Retrovirus contamination in a vaccine is a serious concern because it can render the vaccine ineffective, or include genetic materials from another virus, leading to adverse side effects. FDA regulations require continual monitoring in the production of vaccines. The detection of retroviruses can lead to costly production delays, denial of FDA approval and adverse events that impact public trust.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Raj Udupa for specific details.

Retrovirus Free Cell Line for Vaccine Development

A recently developed retrovirus free cell line, DF-1, has been successfully used in the production of vaccines. DF-1 is reverse transcriptase negative, preventing retroviruses from introducing genetic material into the cell's DNA. By using this cell line to produce a vaccine, developers can ensure that their vaccine will be free of retrovirus contamination, and limit the chance of recombination. This is important because it will reduce the side effects of a vaccine developed from this cell line, and reduce the chance of vaccine recall by the FDA. This cell line is capable of producing both human and animal vaccines, allowing applications in the prevention human diseases and in veterinary medicine as well.

BENEFITS OF DEVEELOPING A VACCINE FROM A RETROVIRUS FREE CELL LINE

  • Retrovirus free cell line reduces risk of contamination and recombination
  • Cell line supports the propagation of a large number of viruses making it useful in many types of research
  • Cell cycle is 24 hours which allows for better yield and faster propagation of virus
  • Prototype of a non-mammalian cell line, allows for use in human and animal applications
  • Well recognized and established as a research tool, published in over 200 publications
  • Retrovirus free cell line gives broader production applications and field of use